New drug cocktails aim to tame tough prostate cancer
NCT ID NCT02861573
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests whether combining the immunotherapy drug pembrolizumab with other treatments can help men with a hard-to-treat form of prostate cancer that has spread and stopped responding to hormone therapy. About 1,200 participants will receive different drug combinations across ten groups. The goal is to see if these combinations can shrink tumors or slow the disease, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Call for Information (Investigational Site 0008)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Call for Information (Investigational Site 0016)
RECRUITINGSeattle, Washington, 98109, United States
-
Call for Information (Investigational Site 0019)
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
Call for Information (Investigational Site 2041)
RECRUITINGAurora, Colorado, 80045, United States
-
Call for Information (Investigational Site 2090)
RECRUITINGGermantown, Tennessee, 38138, United States
-
Call for Information (Investigational Site 2091)
RECRUITINGCleveland, Ohio, 44195, United States
-
Call for Information (Investigational Site 2094)
RECRUITINGPortland, Oregon, 97239, United States
-
MSD Australia
RECRUITINGNorth Ryde, Australia
Contact Phone: •••-•••-••••
-
MSD Comercializadora, S. de R.L. de C.V.
RECRUITINGMexico City, Mexico
Contact Phone: •••-•••-••••
-
MSD Denmark
RECRUITINGGlostrup Municipality, Denmark
Contact Phone: •••-•••-••••
-
MSD France
RECRUITINGParis, France
Contact Phone: •••-•••-••••
-
MSD Ireland (Human Health) Ltd.
RECRUITINGDublin, Ireland
Contact Phone: •••-•••-••••
-
MSD Italia S.r.l.
RECRUITINGRome, Italy
Contact Phone: •••-•••-••••
-
MSD Polska Sp. Z o.o.
RECRUITINGWarsaw, Poland
Contact Phone: •••-•••-••••
-
MSD Sweden
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-••••
-
Merck Canada
RECRUITINGKirkland, Quebec, H9H 4M7, Canada
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme (New Zealand) Ltd.,
RECRUITINGAuckland, New Zealand
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme BV
RECRUITINGHaarlem, Netherlands
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Ilaclari Ltd. Sti
RECRUITINGIstanbul, Turkey (Türkiye)
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Ltd.
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-••••
-
Merck Sharp and Dohme de Espana S.A.
RECRUITINGMadrid, Spain
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.